Neumora Therapeutics, Common Stock Market Value
| NMRA Stock | 1.28 0.12 8.57% |
| Symbol | Neumora |
Neumora Therapeutics, Price To Book Ratio
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neumora Therapeutics,. If investors know Neumora will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neumora Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Neumora Therapeutics, is measured differently than its book value, which is the value of Neumora that is recorded on the company's balance sheet. Investors also form their own opinion of Neumora Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Neumora Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neumora Therapeutics,'s market value can be influenced by many factors that don't directly affect Neumora Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neumora Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Neumora Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neumora Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Neumora Therapeutics, 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Neumora Therapeutics,'s stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Neumora Therapeutics,.
| 12/14/2024 |
| 03/14/2025 |
If you would invest 0.00 in Neumora Therapeutics, on December 14, 2024 and sell it all today you would earn a total of 0.00 from holding Neumora Therapeutics, Common or generate 0.0% return on investment in Neumora Therapeutics, over 90 days. Neumora Therapeutics, is related to or competes with Suntory Beverage, NioCorp Developments, SNDL, East Africa, Compania Cervecerias, and Monster Beverage. Neumora Therapeutics, is entity of United States More
Neumora Therapeutics, Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Neumora Therapeutics,'s stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Neumora Therapeutics, Common upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.12) | |||
| Maximum Drawdown | 88.09 | |||
| Value At Risk | (8.14) | |||
| Potential Upside | 6.72 |
Neumora Therapeutics, Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Neumora Therapeutics,'s investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Neumora Therapeutics,'s standard deviation. In reality, there are many statistical measures that can use Neumora Therapeutics, historical prices to predict the future Neumora Therapeutics,'s volatility.| Risk Adjusted Performance | (0.11) | |||
| Jensen Alpha | (1.39) | |||
| Total Risk Alpha | 0.3465 | |||
| Treynor Ratio | (1.72) |
Neumora Therapeutics, Backtested Returns
Neumora Therapeutics, has Sharpe Ratio of -0.16, which conveys that the firm had a -0.16 % return per unit of risk over the last 3 months. Neumora Therapeutics, exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify Neumora Therapeutics,'s Standard Deviation of 11.03, mean deviation of 4.98, and Risk Adjusted Performance of (0.11) to check out the risk estimate we provide. The company secures a Beta (Market Risk) of 0.88, which conveys possible diversification benefits within a given portfolio. Neumora Therapeutics, returns are very sensitive to returns on the market. As the market goes up or down, Neumora Therapeutics, is expected to follow. At this point, Neumora Therapeutics, has a negative expected return of -1.86%. Please make sure to verify Neumora Therapeutics,'s maximum drawdown, accumulation distribution, as well as the relationship between the Accumulation Distribution and day typical price , to decide if Neumora Therapeutics, performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.79 |
Good predictability
Neumora Therapeutics, Common has good predictability. Overlapping area represents the amount of predictability between Neumora Therapeutics, time series from 14th of December 2024 to 28th of January 2025 and 28th of January 2025 to 14th of March 2025. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Neumora Therapeutics, price movement. The serial correlation of 0.79 indicates that around 79.0% of current Neumora Therapeutics, price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.79 | |
| Spearman Rank Test | 0.79 | |
| Residual Average | 0.0 | |
| Price Variance | 0.03 |
Neumora Therapeutics, lagged returns against current returns
Autocorrelation, which is Neumora Therapeutics, stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Neumora Therapeutics,'s stock expected returns. We can calculate the autocorrelation of Neumora Therapeutics, returns to help us make a trade decision. For example, suppose you find that Neumora Therapeutics, has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Neumora Therapeutics, regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Neumora Therapeutics, stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Neumora Therapeutics, stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Neumora Therapeutics, stock over time.
Current vs Lagged Prices |
| Timeline |
Neumora Therapeutics, Lagged Returns
When evaluating Neumora Therapeutics,'s market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Neumora Therapeutics, stock have on its future price. Neumora Therapeutics, autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Neumora Therapeutics, autocorrelation shows the relationship between Neumora Therapeutics, stock current value and its past values and can show if there is a momentum factor associated with investing in Neumora Therapeutics, Common.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Neumora Therapeutics, offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Neumora Therapeutics,'s financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neumora Therapeutics, Common Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neumora Therapeutics, Common Stock:Check out Neumora Therapeutics, Correlation, Neumora Therapeutics, Volatility and Neumora Therapeutics, Alpha and Beta module to complement your research on Neumora Therapeutics,. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Neumora Therapeutics, technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.